MarketVIEW RNA & Zoonotic Virus Vaccines  ·  November 2019 edition

Lassa Fever Virus
Vaccines Forecast

Lassa fever has quietly claimed thousands of lives across West Africa every dry season for decades, and Nigeria's 2025 outbreak has already produced the country's deadliest toll on record. That same period has delivered the field's first-ever Phase 2 vaccine trial and a new viral vector candidate dosing its first human volunteer. This is the independent commercial assessment of what a workable vaccine could be worth, drawing on VacZine Analytics' long-standing, independent authority in RNA virus and zoonotic disease vaccine markets.

Nigeria's Worst Lassa Season on Record (2025) IAVI rVSV Candidate Now Phase 2a Oxford ChAdOx1 First-in-Human (2025) CEPI/WHO Priority Pathogen
Product catalogue
VAMV080
November 2019 edition

Format
PDF (~150 slides) + Excel
Coverage
West Africa + relevant geographies
Vaccines assessed
IAVI rVSV, Oxford ChAdOx1, INO-4500
Scenarios
Preventative + emergency response
Approach
Case-study benchmarked (Ebola)
Base edition
November 2019
Availability
Syndicated / bespoke
100-300K
Estimated Lassa fever infections
in West Africa per year
24%
Case fatality rate in Nigeria's
2025 Lassa fever season
1 in 3
Survivors affected by
deafness, often permanent
2025
Year IAVI's Phase 2a trial expanded
and Oxford's ChAdOx1 dosed its first volunteer
Disease background

Why Lassa fever remains a CEPI/WHO priority pathogen

Lassa fever is a seasonal, chronically under-surveyed threat that resurfaces every dry season across West Africa, and 2025 has been its worst on record in Nigeria. Understanding both its historical burden and the vaccine candidates now moving through clinical development is central to understanding what a workable vaccine could be worth.

NCDC surveillance & 2025/2026 pipeline data

Pathogen overview - Lassa virus (LASV)

Lassa fever is an acute viral haemorrhagic illness caused by Lassa virus (LASV), a single-stranded RNA virus of the Arenaviridae family. The virus is zoonotic, transmitted mainly from its rodent host, Mastomys natalensis (the multimammate rat), to humans, where it can cause symptoms ranging from fever, general malaise, weakness and headache to multi-organ failure or death in severe cases. A significant cause of morbidity among survivors is deafness, which occurs in approximately one-third of cases and can be permanent.

Historical WHO estimates put annual Lassa fever infections in West Africa at between 100,000 and 300,000, resulting in approximately 5,000 deaths, though these figures are widely regarded as outdated and constrained by a longstanding lack of routine surveillance. Intravenous ribavirin, if given early, can reduce mortality, but there is no licensed vaccine.

Nigeria's outbreak record has since sharpened that picture considerably. In 2024, Nigeria's Centre for Disease Control and Prevention (NCDC) reported 10,450 confirmed cases and 184 deaths across 28 of the country's 36 states and the federal capital territory, with Ondo, Edo and Bauchi states accounting for 62% of all confirmed cases. By 2025, Nigeria had already recorded over 220 deaths, surpassing the prior year's toll, with the outbreak spreading to 23 states and a case fatality rate of approximately 24%, the highest in recent memory. Transmission is highly seasonal, peaking in the dry season as food scarcity drives increased rodent-human interaction, and many deaths are linked to delayed treatment-seeking and poor environmental sanitation in affected communities.

LASV has been designated a priority pathogen by the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organisation, which has committed approximately 250 million US dollars to Lassa fever vaccine research and development to date. That investment is now translating into clinical progress on two fronts. IAVI's rVSV-based candidate, built on the same recombinant vesicular stomatitis virus platform as Merck's licensed Ebola vaccine ERVEBO, launched the field's first-ever Phase 2a trial in Nigeria in April 2024, since expanded to Ghana and Liberia, enrolling around 612 participants across adults, adolescents and children as young as two. In December 2025, Oxford and CEPI's ChAdOx1 Lassa candidate dosed its first human volunteer in a first-in-human Phase 1 trial in the UK, with further sites planned in Ghana and completion estimated for September 2027.

2026 10,450 Nigeria cases in 2024, 184 deaths  |  over 220 deaths and 24% CFR in 2025  |  IAVI rVSV now Phase 2a across West Africa  |  Oxford ChAdOx1 dosing first volunteers
Product & competitor landscape

The field's first Phase 2 trial, and a viral vector candidate right behind it

Lassa fever vaccine development has historically been constrained by unpredictable, seasonal outbreak patterns and thin commercial incentives. CEPI's sustained investment has changed that, with one candidate now in the field's first-ever Phase 2 trial and a second dosing its first human volunteers.

  • IAVIPhase 2a (2024/25)
    rVSVΔG-LASV-GPC (C105) Viral vector
    Built on the same recombinant vesicular stomatitis virus platform as Merck's licensed Ebola vaccine ERVEBO. Following Phase 1 safety and immunogenicity data from the US and Liberia, the field's first-ever Phase 2a Lassa vaccine trial launched in Nigeria in April 2024, since expanded to Ghana and Liberia, enrolling approximately 612 participants across adults (including people living with HIV), adolescents and children aged two and above.
  • Oxford / CEPIPhase 1 (2025)
    ChAdOx1 Lassa Viral vector
    Uses the same chimpanzee adenovirus vector platform as the Oxford-AstraZeneca COVID-19 vaccine and the ChAdOx1 RVF candidate. First human volunteer dosed in December 2025 in a first-in-human Phase 1 trial in the UK; the trial expanded to a second site, Ghana's Kintampo Health Research Centre, in October 2026, enrolling up to 51 additional healthy adults, with completion still estimated for September 2027.
  • InovioPhase 1
    INO-4500 DNA vaccine
    The first Lassa fever vaccine candidate to enter clinical testing, in 2019, using Inovio's synthetic DNA platform. Remains in earlier-stage clinical development relative to the rVSV and viral vector frontrunners.
  • SK Bioscience / academic programmesPreclinical
    mRNA and other early-stage candidates
    SK Bioscience's rapid-response mRNA platform is being tested against Lassa fever as a representative "Disease X" target pathogen, alongside earlier academic candidates including Institut Pasteur's MOPEVAC and Thomas Jefferson University's LASSARAB.
Inflection point
2025

2025 delivered both the field's worst outbreak year and its most significant clinical progress: Nigeria's deadliest recorded Lassa fever season struck the same year that IAVI's rVSV candidate expanded its landmark Phase 2a trial across three West African countries and Oxford's ChAdOx1 dosed its first human volunteer. With CEPI's approximately 250 million US dollar commitment now spread across multiple platforms, the case for a deployable vaccine has rarely been stronger. The VacZine Analytics model quantifies the commercial opportunity under multiple outbreak-frequency and pipeline-progression scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW Lassa fever analysis spans disease burden, target population rationale, the post-2025 competitor landscape and scenario-based commercial forecasting across preventative and emergency-response vaccination scenarios.

Target population forecast

Commercial potential of a putative Lassa fever vaccine across all relevant target groups, modelled under both preventative and emergency-response scenarios.

Competitor & pipeline review

IAVI's Phase 2a rVSV candidate, Oxford/CEPI's ChAdOx1 in first-in-human testing, Inovio's INO-4500, and SK Bioscience's mRNA and academic programmes.

Platform & vaccinology assessment

Viral vector (rVSV, ChAdOx1), DNA and mRNA platform comparison, and their manufacturability implications for outbreak response.

Case-study benchmarked forecasts

Detailed case study analyses of Ebola vaccine procurement and deployment, and other African endemic disease launches, informing all model assumptions.

Disease burden & outbreak surveillance

Historical West Africa burden estimates alongside Nigeria's 2024 and record 2025 NCDC outbreak data, including deafness sequelae in survivors.

CEPI/WHO policy & procurement landscape

Review of CEPI's approximately 250 million US dollar investment programme and its implications for procurement pathways and vaccine access.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full commercial outputs, pricing assumptions and case-study benchmarks are in the licensed model.

Target populationGeographyScenario typeVaccine profileValue scenario
Rural endemic-zone populationsNigeria, Ghana, LiberiaPreventativeRoutine / targetedModelled
Healthcare worker occupational riskWest AfricaPreventativeOccupationalModelled
Outbreak emergency responseWest Africa (reactive)EmergencyStockpiled / reactiveModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseWest AfricaAllAll profiles$███m
Full model in the licensed workbook
Preventative + emergency · case-study benchmarked · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a commercial forecast model, built for decision-makers who need the full picture on the Lassa fever vaccine opportunity.

  • Executive presentation (~150 slides, PDF) - disease background, epidemiology, outbreak history through 2025, competitor pipeline and full commercial assessment with supporting narrative and references
  • MS-Excel forecast model - commercial potential of a putative Lassa fever vaccine across all relevant target groups, preventative and emergency scenarios
  • Case study analyses - Ebola vaccine procurement and deployment, and other African endemic disease launches, used to benchmark all model assumptions
  • Competitor intelligence - IAVI's Phase 2a rVSV candidate, Oxford/CEPI's ChAdOx1, Inovio's INO-4500, and SK Bioscience's mRNA and academic programmes
  • Updated epidemiology & outbreak module - historical West Africa burden estimates plus Nigeria's 2024 and record 2025 NCDC outbreak data
  • CEPI/WHO policy review - the approximately 250 million US dollar investment programme and its implications for procurement and access
Target audience

Built for organisations weighing the Lassa fever opportunity

Most valuable to teams evaluating the Lassa fever vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of Nigeria's record 2025 outbreak and the two CEPI-backed candidates now advancing through clinical development.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for Lassa fever candidates at any stage.

Corporate strategy & BD

Validate market size and structure now that two CEPI-backed candidates are progressing through Phase 1 and 2 trials.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on Lassa fever and adjacent zoonotic/RNA virus vaccine assets.

Public health & pandemic preparedness

Demand modelling for outbreak-response and CEPI-aligned epidemic preparedness programmes across West Africa.

Researchers & academia

Comprehensive epidemiology and vaccine landscape for grant and translational planning, including outbreak surveillance data.

Market access & policy

Pricing benchmarks and access-pathway assumptions across public procurement and outbreak-stockpile channels.

About this analysis · VAMV080

VacZine Analytics has tracked RNA virus and zoonotic disease vaccine markets since our earliest editions, positioning us to reassess the Lassa fever opportunity the moment the outbreak record and pipeline both shifted. This analysis combines a rigorous epidemiological and outbreak-surveillance review with an independently constructed commercial model spanning preventative and emergency-response scenarios that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis, which has been well received by clients across the field.

This November 2019 edition has been updated to incorporate Nigeria's 2024 and record 2025 outbreak data, IAVI's expanded Phase 2a rVSV trial across Nigeria, Ghana and Liberia, and the December 2025 first-in-human dosing of Oxford/CEPI's ChAdOx1 candidate. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV080 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Lassa fever analysis, a briefing call is included on request.